Premium
mTOR Inhibitors as Primary Immunosuppression After Heart Transplant: Confounding Factors in Clinical Trials
Author(s) -
Kushwaha S. S.
Publication year - 2014
Publication title -
american journal of transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.89
H-Index - 188
eISSN - 1600-6143
pISSN - 1600-6135
DOI - 10.1111/ajt.12832
Subject(s) - medicine , immunosuppression , confounding , discovery and development of mtor inhibitors , pi3k/akt/mtor pathway , clinical trial , heart transplantation , sirolimus , intensive care medicine , oncology , transplantation , signal transduction , biochemistry , chemistry
This editorial provides insight into the acute rejection rates in the original multicenter study of sirolimus conversion for heart transplantation, and suggests that dose reduction of mycophenolate mofetil prior to conversion is a significant confounding factor resulting in increased rates of rejection. See opposing editorial by Patel (page 1960) and article by Zuckermann et al (page 2048).